HOME >> BIOLOGY >> NEWS
Enzyme inhibitors block replication of SARS virus

ve been looking at other Liponavir-related compounds for similar blocking effects. During these experiments, they found that a group of catalyzing agents used to help promote chemical reactions in the laboratory were actually more powerful in blocking the SARS protease than either the Lopinavir or any of the target compounds.

These organic compounds are called benzotriazole esters. The esters entered the SARS protease site, formed an intermediary compound, then inactivated the SARS enzyme. The findings were confirmed using mass spectrometry analysis of the enzyme intermediary.

"These benzotriazole esters are relatively stable and act as suicide inhibitors," Wong said. "They block the enzyme, are transformed through a co-valent bond, and are unable to get out."

Wong said the findings published today provide better insight into the mode of action of the enzyme, which may lead to development of a drug against SARS. The findings were made by using rapid drug discovery techniques developed in the Wong lab to screen large numbers of weak enzyme inhibitors, and then attaching additional compounds to look for stronger reactions.

Research Associate Chung-Yi Wu, a member of the Wong lab, is the paper's lead author. He said the finding was unexpected.

"We wanted to improve Liponavir activity," Wu said. "But we found this very surprising and serendipitous result."


'"/>

Contact: Keith McKeown
kmckeown@scripps.edu
858-784-8134
Scripps Research Institute
28-Mar-2006


Page: 1 2

Related biology news :

1. Enzyme discovery sheds light on vitamin D
2. Enzyme delivered in smaller package protects cells from radiation damage
3. Enzyme Engineering XIX
4. Enzyme inhibitor produces stable disease in patients with advanced solid cell cancers
5. Enzyme shreds Alzheimers protein
6. Enzyme defect leads to hyperinsulinism
7. Eat less, weigh more? Enzyme makes lean mice susceptible to dietary fat
8. Enzyme crystal structure reveals unexpected genome repair functions
9. Enzyme may be target for new anti-inflammatory compounds
10. Enzyme action creates protein linked to Alzheimers disease
11. Enzyme deficiency may contribute to liver cancer, Mount Sinai research indicates

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Enzyme inhibitors block replication SARS virus

(Date:5/22/2015)... OXFORD, CT , May 22, 2015  NXT-ID, Inc. ... from June 1st, it will be ending its promotional pricing ... www.wocketwallet.com . Laurence Savin , Head of ... our exclusive promotional pricing until the end of May. To ... at wocketwallet.com/invite and when we open the store on June ...
(Date:5/20/2015)... , May 20, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/h8t4x6/5year ) has announced the addition ... the Global Iris Recognition Market"  report ... , ,This research service analyses trends ... the government and commercial sectors, globally. ...
(Date:5/19/2015)... , May 19, 2015 ... has announced the addition of the  "Genetic ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent ... an in-depth analysis of the current and ... of gene-based tests, their working principles and ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Global Genetic Testing Market Outlook 2018 2
(Date:5/26/2015)... May 26, 2015 Tianyin Pharmaceutical Inc. (NYSE ... in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), ... the Company,s Annual Meeting of Shareholders for fiscal year ... held at the Company,s office located in ... 9:00 AM (local time in Chengdu, China ...
(Date:5/26/2015)... 26, 2015 Pharmaco-Kinesis Corporation (PKC) announced today ... at Shutters on the Beach in Santa ... of the Company,s innovative Metronomic Biofeedback Pump (MBP), a ... chemotherapy over time to a target site of the ... biofeedback system in real-time.  ...
(Date:5/26/2015)... May 26, 2015 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of oral ... the study protocol for the company,s Phase IIb trial ... Food and Drug Administration (FDA). The submission was made ... The Phase IIb study of ORMD-0801 for ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 Just the ... a long-standing unmet biomedical need does not guarantee immediate ... problem that has seen many prior failures is often ... acceptance and use is an irony that is often ... small, new start-up company, Asymmetrex has found ...
Breaking Biology Technology:TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 2TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 2Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 4Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 5Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 2Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 3In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 2In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 3
Cached News: